Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14787
Abstract: The randomized phase III ELOQUENT‐2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma. ELd reduced the risk of disease progression/death by 30% versus Ld… read more here.
Keywords: dexamethasone relapsed; eld; versus; progression ... See more keywords
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Haematology"
DOI: 10.1111/ejh.13058
Abstract: OBJECTIVE To evaluate the efficacy and safety of elotuzumab and dexamethasone (Ed) for relapsed or refractory multiple myeloma (RRMM) patients. METHOD This retrospective study evaluated the efficacy and safety of Ed treatment for 21 RRMM… read more here.
Keywords: relapsed refractory; dexamethasone relapsed; refractory multiple; multiple myeloma ... See more keywords
Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.8025
Abstract: 8025Background: Daratumumab (D) is a human CD38-targeting mAb that significantly prolongs progression-free survival (PFS) when added to standard-of-care regimens in patients (pts) with RRMM. We exa... read more here.
Keywords: dexamethasone relapsed; drd lenalidomide; dexamethasone drd; dexamethasone ... See more keywords